Michael Wheatcroft
Director Técnico/Científico/I+D en TELIX PHARMACEUTICALS LIMITED .
Cargos activos de Michael Wheatcroft
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| TELIX PHARMACEUTICALS LIMITED | Director Técnico/Científico/I+D | - | - |
Historial de carrera de Michael Wheatcroft
Antiguos cargos conocidos de Michael Wheatcroft.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Medimmune UK Ltd.
 Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Corporate Officer/Principal | - | - |
Avipep Pty Ltd.
 Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Corporate Officer/Principal | - | - |
Formación de Michael Wheatcroft.
| University of Cambridge | Doctorate Degree |
Estadísticas
Internacional
| Reino Unido | 3 |
| Australia | 3 |
Operativa
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 2 |
| Process Industries | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| TELIX PHARMACEUTICALS LIMITED | Health Technology |
| Empresas privadas | 2 |
|---|---|
Medimmune UK Ltd.
Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Process Industries |
Avipep Pty Ltd.
Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Health Technology |
- Bolsa de valores
- Insiders
- Michael Wheatcroft
- Experiencia
